Corsair Pharma is developing transformative solutions to the therapeutic profile of medications and provide superior treatment for patients.
Corsair Pharma has raised $23.0M in total funding. The most recent round was Series B. The last funding was announced in September 2023.
Corsair Pharma's investors include Primavera Capital Group, New Rhein, Junson Capital, Plaisance Capital Management, Midas Capital.
Corsair Pharma is headquartered in Sunnyvale, United States.
Corsair Pharma is developing transformative solutions to the therapeutic profile of medications and provide superior treatment for patients.
Corsair Pharma is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Corsair Pharma — Funding & Investors." VCBacked, September 20, 2023, https://www.vcbacked.co/company/corsair-pharma. Accessed August 14, 2026.
VCBacked. (2023). Corsair Pharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/corsair-pharma
{{cite web |title=Corsair Pharma — Funding & Investors |url=https://www.vcbacked.co/company/corsair-pharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated